Elicio Therapeutics
ELTX
47 hedge funds and large institutions have $69.3M invested in Elicio Therapeutics in 2021 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 22 increasing their positions, 4 reducing their positions, and 8 closing their positions.
450% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 4
75% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 8
15% more funds holding
Funds holding: 41 → 47 (+6)
6.84% more ownership
Funds ownership: 16.95% → 23.79% (+6.8%)
4% more capital invested
Capital invested by funds: $66.5M → $69.3M (+$2.77M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.96M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.01M |
| 3 |
Russell Investments Group
London,
United Kingdom
|
+$2.68M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.63M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
-$779K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$744K |
| 3 |
Millennium Management
New York
|
-$626K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$420K |
| 5 |
JP Morgan Chase
New York
|
-$396K |
ELTX Hedge Fund Activity: Q3 2021 in Review
47 of the 5,729 institutional investors tracked by Wall St. Rank reported a position in Elicio Therapeutics (ELTX) for Q3 2021, worth a combined $69.3M — up 4.2% from $66.5M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new ELTX positions and 8 closed out — a net gain of 6 holders — while 22 added to existing stakes and 4 trimmed.
The largest buyer was BlackRock, adding an estimated $7.96M. The largest seller was HRT Financial, exiting entirely with an estimated $779K sold.
- 47 institutional investors held Elicio Therapeutics (ELTX) as of Q3 2021, up from 41 in Q2 2021.
- Funds reported $69.3M of Elicio Therapeutics stock for Q3 2021, up 4.2% quarter-over-quarter.
- 14 funds opened new Elicio Therapeutics positions in Q3 2021 and 8 closed out, a net change of +6 holders.
- The largest Elicio Therapeutics buyer in Q3 2021 was BlackRock, an estimated $7.96M added.
- The largest Elicio Therapeutics seller in Q3 2021 was HRT Financial, an estimated $779K sold.
Based on aggregated 13F filings for Q3 2021.